21 results about "Allopurinol" patented technology

The invention discloses a preparation method of an astragalus extract with a uric acid reducing effect, and belongs to the technical field of biological medicines. The method comprises the following steps: concentrating an ethanol extract of radix astragali, extracting by using n-butyl alcohol, ethyl acetate and petroleum ether respectively, and concentrating an extract to obtain n-butyl alcohol, ethyl acetate and petroleum ether extraction parts and residual parts respectively, so as to obtain an n-butyl alcohol extract, namely the radix astragali extract for reducing uric acid. Efficacy experiments show that the normal butanol extraction part of the ethanol extract of the astragalus membranaceus can obviously reduce the serum uric acid level (SUA) of a mouse with hyperuricemia, inhibit the activity of xanthine oxidase (XOD) and effectively improve kidney injury caused by the hyperuricemia. The uric acid reducing effect of the radix astragali n-butyl alcohol extract is close to that of a clinical drug allopurinol, and the radix astragali n-butyl alcohol extract has wide development and application prospects in the aspect of relieving hyperuricemia.

The present invention provides a pharmaceutical composition comprising a therapeutically effective amount of allopurinol, febuxostat, or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating cardiovascular disease, in which the composition is administered to a subject having a serum uric acid level of 6 mg / dl or higher to reduce the serum uric acid level of the subject to less than 6 mg / dl. Therefore, the pharmaceutical composition according to the present invention exhibits an excellent effect on xanthine oxidase inhibitor and is administered to selected subjects to effectively treat or prevent cardiovascular disease.

The application discloses a tetrapeptide IR4 with uric acid reducing activity, and a preparation method and application thereof, and belongs to the technical field of small molecular peptides. The amino acid sequence of the tetrapeptide IR4 is IDWR, and the tetrapeptide IR4 can be prepared by a solid-phase synthesis method and an enzymatic hydrolysis method. The tetrapeptide IR4 is identified from a porphyra haitanensis protease hydrolysate, has potential interaction with xanthine oxidase, and can reduce the uric acid content of zebrafish by 33.6% (to 5.93+ / -0.47 mu mol / g protein) at a concentration of 100 mu g / mL. Compared with an anserine (which can reduce the uric acid content of zebrafish by 25.7%), the tetrapeptide IR4 has better uric acid reducing activity. Compared with allopurinol (which can reduce the uric acid content of zebrafish to 4.61+ / -1.11 mu mol / g protein), the uric acid reducing ability of the tetrapeptide IR4 and the allopurinol has no significant difference. The tetrapeptide IR4 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

The application discloses a pentapeptide IK5 with uric acid reducing activity as well as a preparation method and application thereof, and belongs to the technical field of small molecular peptides. The amino acid sequence of the pentapeptide IK5 is ITGYK, and the pentapeptide IK5 can be prepared by a solid-phase synthesis method and an enzymolysis method. The pentapeptide IK5 is identified from a protease enzymolysis liquid of a fine weak red winged seaweed, has potential interaction with xanthine oxidase, and can reduce the uric acid content of zebrafish by 44.4% (to 5.93+ / -0.47 mu mol / g protein) at a concentration of 100 mu g / mL. Compared with ananeine (which can reduce the uric acid content of zebrafish by 25.7%), the pentapeptide IK5 has better uric acid reducing activity. Compared with allopurinol (which can reduce the uric acid content of zebrafish to 4.61+ / -1.11 mu mol / g protein), the uric acid reducing ability of the pentapeptide IK5 and the allopurinol has no significant difference. The pentapeptide IK5 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

The application discloses application of low-molecular pachyman in preparation of a medicine for simultaneously relieving hyperuricemia and liver and kidney injury, and belongs to the technical field of biological medicine. The application finds through experiments that the low-molecular pachyman has good uric acid lowering effect, and the cytotoxicity result shows that the low-molecular pachyman (0-2000 mu g / mL) has no significant toxicity to liver and kidney cells; meanwhile, the application also finds that the low-molecular pachyman can relieve liver and kidney injury caused by allopurinol and benzbromarone when lowering uric acid. Therefore, the low-molecular pachyman in the application has a good application prospect in relieving hyperuricemia caused by oxypurinol and antagonizing liver and kidney injury caused by drugs.

The utility model relates to the technical field of allopurinol preparation, in particular to a multi-effect evaporation device which comprises a base, evaporation cavities are evenly and fixedly installed on the base, communicating pipes are installed among the three evaporation cavities, a rotating frame is arranged on the base in a sliding mode, evaporation tanks are evenly installed on the rotating frame, and the communicating pipes are communicated with the evaporation tanks. A threaded rod is fixedly installed on the base, a rotating disc is rotatably installed on the rotating frame, a threaded sleeve is rotatably installed on the rotating disc, a motor is fixedly installed on the rotating disc, a gear set is installed between the motor and the threaded sleeve, and the threaded sleeve is meshed with the threaded rod. The motor is started to drive the threaded sleeve to rotate anticlockwise through the gear set, so that the threaded sleeve pulls the rotating frame to slide upwards through the rotating disc, the evaporation tank is separated from the evaporation cavity, then the rotating frame is pushed to rotate, station switching can be rapidly carried out, and raw materials do not need to be transferred among different efficiency levels.

The invention discloses a method for determining the dissolution rate and the dissolution curve of purinol tablets. The dissolution rate of the allopurinol tablets is detected by high performance liquid chromatography instead of an ultraviolet spectrophotometer method used at present. According to the method, a chromatographic column is used as a silica gel bonded octadecylsilane column, an acid solution-organic phase is used as a mobile phase, and an isocratic elution mode is adopted for detection. According to the method for detecting the dissolution rate and the dissolution curve of the allopurinol tablet through the high performance liquid chromatography, detection can be easily and conveniently completed, specificity is high, accuracy is high, repeatability is good, application and linearity are achieved, and the dissolution rate of the allopurinol tablet and the dissolution amount of the dissolution curve can be efficiently and rapidly detected.

The utility model relates to the technical field of allopurinol preparation, and particularly discloses a micro-channel reactor which is characterized in that a hollow mounting ring is arranged in a glass type reactor body, four shunting check rings are arranged in the hollow mounting ring, and a group of comb-tooth-shaped baffles are arranged in each shunting check ring; a reactant is injected into the glass type reactor body along the feeding base, at an inlet of the glass type reactor body, the reactant encounters multiple layers of shunting check rings, a group of comb-tooth-shaped baffles are installed in each shunting check ring, every two of the four comb-tooth-shaped baffles are distributed in a staggered mode, the reactant is shunted into a plurality of fine streams by the first comb-tooth-shaped baffle, and the fine streams are distributed in a staggered mode by the second comb-tooth-shaped baffle. The directions of the streams are changed in the flowing process, then the streams are re-shunted and disorganized on the second-layer comb-tooth-shaped baffle, then the process is repeated, the shunting process is continuously repeated, and in this way, reactants are in full contact and mixed, and good conditions are created for the reaction of allopurinol.

The application discloses a composition with a function of reducing uric acid and a preparation process thereof, which is prepared from the following raw materials in parts by weight: 10-30 parts of chicory, 5-20 parts of gardenia, 5-15 parts of mulberry leaves, 5-15 parts of radix puerariae, 10-20 parts of coix seed, 5-15 parts of poria cocos, and 2-8 parts of licorice root. The application has the beneficial effects that: the seven kinds of medicine and food homologous medicinal materials such as chicory and gardenia are scientifically matched, uric acid is reduced through the double ways of inhibiting xanthine oxidase activity and promoting uric acid excretion, the animal experiment shows that the effect is better than that of the positive drug allopurinol, and the safety is high, and there is no toxic side effect; the preparation process is simple, there is no organic solvent residue, various oral dosage forms can be prepared, and the application is suitable for the auxiliary conditioning of hyperuricemia and gout.

The invention discloses a traditional Chinese medicine composition for treating hyperuricemia as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from semen hoveniae, radix puerariae, semen phaseoli, raw fructus gardeniae, herba taraxaci, poria cocos and rhizoma dioscoreae. According to the traditional Chinese medicine composition, dissolution of effective components is improved through a combined mode of decocting radix puerariae first and decocting other medicines together, dialectical components are adopted, whole-course intervention of upstream generation inhibition, midstream dissolution and crystallization and downstream excretion promotion on hyperuricemia metabolic disorder can be achieved, and the effect of treating hyperuricemia metabolic disorder can be achieved through physique conditioning, heat clearing and diuresis promoting, spleen strengthening and kidney tonifying, detoxification and turbid descending, collateral dredging and blood stasis dissipating. The blood uric acid level and inflammation balance are successfully recovered to a physiological state, and the action mode is superior to a traditional single uric acid reducing strategy and a traditional Chinese medicine application mode of decocting the whole formula simultaneously. In an animal model, the composition has the effects of remarkably reducing uric acid, regulating inflammation, protecting kidney and improving overall physique, the curative effect of a high-dose group is equivalent to that of a classic uric acid reducing medicine allopurinol, and the composition has more advantages in the aspects of kidney pathological repair and long-term safe conditioning.

The invention discloses pentapeptide IK5 with uric acid reducing activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptide. The amino acid sequence of the pentapeptide IK5 is ITGYK, and the pentapeptide IK5 can be prepared through a solid-phase synthesis method and an enzymolysis method. The pentapeptide IK5 is identified from a solieria tenuissima proteolysis solution, has potential interaction with xanthine oxidase, can reduce the uric acid content of zebra fish by 44.4% (reduced to 5.93 + / -0.47 [mu] mol / g protein) when the concentration is 100 [mu] g / mL, and has better uric acid reducing activity compared with goose carnosine (which can reduce the uric acid content of zebra fish by 25.7%). Compared with allopurinol (the uric acid content of zebra fish can be reduced to 4.61 + / -1.11 [mu] mol / g protein), the pentapeptide IK5 and allopurinol have no significant difference in uric acid reducing capacity, and the pentapeptide IK5 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

The application discloses a hyperuricemia non-human primate model and a construction method thereof, and belongs to the technical field of experimental animals. The construction method comprises the following steps: using a non-human primate, i.e., a cynomolgus monkey, as a model animal, orally administering potassium oxonate and intravenously injecting myo-inositol, so that the blood uric acid content of the cynomolgus monkey is significantly increased within 0.5-8 hours, and the process can be inhibited by a uric acid-lowering drug allopurinol, and based on this, a hyperuricemia model of a non-human primate can be formed. Compared with a model constructed by using rodents, the hyperuricemia non-human primate model constructed by the application can better simulate the related symptoms and physiological processes of human hyperuricemia, and provides a preclinical effect evaluation tool for the research and development of nutrients and drugs in related fields.

This invention provides an application of *Lactobacillus plantarum* peptidoglycan in the preparation of uric acid-lowering products, relating to the biomedical field. This *Lactobacillus plantarum* peptidoglycan is derived from *Lactobacillus plantarum* (accession number CGMCC No. 25306). Lactobacillus plantarum Extracted from YC, its chemical structure is A1γ. This plant lactobacillus peptidoglycan can regulate uric acid homeostasis through multiple synergistic mechanisms: inhibiting hepatic XOD activity to reduce uric acid production; bidirectionally regulating renal and intestinal uric acid transport proteins (upregulating ABCG2 / OAT1, downregulating URAT1 / GLUT9) to promote excretion; and exerting systemic anti-inflammatory and hepatoprotective effects. This plant lactobacillus peptidoglycan has a significant uric acid-lowering effect without hepatotoxicity or nephrotoxicity, and its safety is superior to allopurinol. This invention provides a novel core material basis and solution for developing multi-pathway, highly safe uric acid-lowering products.

The invention discloses a preserving fluid for preserving pancreatic cancer tissues and application of the preserving fluid. The preserving fluid is prepared from mannitol, reduced glutathione, allopurinol, magnesium sulfate, gabexate mesylate, orlistat, pyruvic acid, Primocin, dexamethasone, heparin, bovine serum albumin, HEPES and the balance of an advance DMEM / F12 culture medium. The preserving fluid has a good effect in maintaining the pancreatic cancer tissue activity and inhibiting self-digestion and oxidative damage, is beneficial to maintaining the cell activity, and is beneficial to the preservation of pancreatic ductal adenocarcinoma in-vitro tissues and the construction of subsequent organoid.

The invention discloses a hexapeptide IL6 with uric acid reducing activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide IL6 is IGGSIL, and the hexapeptide IL6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide IL6 is identified from red algae agar waste residue protein hydrolysate, has potential interaction with xanthine oxidase, and can reduce the uric acid content of zebra fish by 34.9% (reduced to 5.82 + / -0.27 [mu] mol / g protein) when the concentration is 100 [mu] g / mL, and compared with classic uric acid reducing peptide-goose carnosine (which can reduce the uric acid content of zebra fish by 25.7%), the hexapeptide IL6 has higher uric acid reducing activity, and can be used for reducing the uric acid content of zebra fish by 5.82 + / -0.27 [mu] mol / g protein. Compared with allopurinol (the uric acid content of zebra fish can be reduced to 4.61 + / -1.11 [mu] mol / g protein), the hexapeptide IL6 and allopurinol have no significant difference in uric acid reducing capacity, and the hexapeptide IL6 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

The invention discloses a uracil modified quercetin derivative as well as a preparation method and application thereof. The uracil-modified quercetin derivative has the following molecular structure expression, and research finds that the uracil-modified quercetin derivative has a remarkable uric acid reducing effect and shows better application advantages compared with existing uric acid reducing medicine allopurinol which is widely used at present; .

The invention discloses tetrapeptide IR4 with uric acid reducing activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptide. The amino acid sequence of the tetrapeptide IR4 is IDWR, and the tetrapeptide IR4 can be prepared through a solid-phase synthesis method and an enzymolysis method. The tetrapeptide IR4 is identified from porphyra haitanensis proteolysis liquid, has potential interaction with xanthine oxidase, can reduce the uric acid content of zebra fish by 33.6% (reduced to 5.93 + / -0.47 [mu] mol / g protein) when the concentration is 100 [mu] g / mL, and has better uric acid reducing activity compared with goose carnosine (which can reduce the uric acid content of zebra fish by 25.7%). Compared with allopurinol (the uric acid content of zebra fish can be reduced to 4.61 + / -1.11 mu mol / g protein), the tetrapeptide IR4 and allopurinol have no significant difference in uric acid reducing capacity, and the tetrapeptide IR4 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

The utility model discloses an allopurinol bulk drug mixing device which comprises a fixed base, a sliding rail is fixed on the inner side of the fixed base, the top of the sliding rail is connected with a movable base in a sliding mode, four sets of supporting sliding rods are fixed on the top of the fixed base, a lead screw is arranged between every two sets of supporting sliding rods, and the lead screw is connected with the movable base in a sliding mode. A first motor is installed at the top of the lead screw, a cross beam is fixed to the top of the supporting sliding rod, and the first motor is arranged in the cross beam. The first motor is started to drive the lead screw to rotate to drive the cover plate to move downwards, and the connecting plate on the inner side of the cover plate drives the stirring shaft to move downwards to enter the mixing tank; along with downward movement of the cover plate, a sealing ring can be in contact sealing with the mixing tank, then a second motor is started to drive a stirring shaft to rotate through a transmission rod, and raw materials in the mixing tank are mixed, so that the stirring shaft and the stirring blades are moved, more energy is saved, and the stirring shaft and the stirring blades can be replaced more conveniently.

The invention relates to a desalting evaporation method for allopurinol, which belongs to the technical field of chemical separation engineering and functional material preparation, and comprises the following steps: mixing fluorine-containing polyaryletherketone or polyimide rigid framework resin, high-temperature-resistant zwitterionic functional modified anti-scaling filler and aprotic polar organic solvent, carrying out ultrasonic dispersion, standing for defoaming, and drying to obtain the allopurinol. A functional coating liquid is obtained; the functional coating liquid is coated on the inner wall of a heat exchange tube of an MVR (mechanical vapor recompression) evaporator or a multi-effect evaporator, and a compact functional coating is constructed on the inner wall of the heat exchange tube by introducing high-temperature-resistant zwitterionic functional modified anti-scaling filler into fluorine-containing polyaryletherketone or polyimide rigid framework resin; the obvious difference is derived from the zwitterionic polymer brush on the surface of the filler, the zwitterionic polymer brush has extremely high hydration capacity in water, and a layer of super-hydrophilic water barrier effect can be formed on the surface of a coating.

The application discloses a hexapeptide IL6 with uric acid reducing activity, and a preparation method and application thereof, and belongs to the technical field of small molecular peptides. The amino acid sequence of the hexapeptide IL6 is IGGSIL, and the hexapeptide IL6 can be prepared by a solid-phase synthesis method and an enzymolysis method. The hexapeptide IL6 is identified from a protease enzymolysis liquid of red algae agar waste residue, has potential interaction with xanthine oxidase, and can reduce the uric acid content of zebra fish by 34.9% (to 5.82+ / -0.27 mu mol / g protein) when the concentration is 100 mu g / mL. Compared with a classic uric acid reducing peptide, carnosine (which can reduce the uric acid content of zebra fish by 25.7%), the uric acid reducing activity of the hexapeptide IL6 is stronger. Compared with allopurinol (which can reduce the uric acid content of zebra fish to 4.61+ / -1.11 mu mol / g protein), the uric acid reducing ability of the hexapeptide IL6 and the allopurinol has no significant difference. The hexapeptide IL6 can be used for preparing uric acid reducing drugs and relieving hyperuricemia.

The present invention provides a pharmaceutical composition comprising as an active ingredient a therapeutically effective amount of allopurinol, febuxostat or a pharmaceutically acceptable salt thereof for the prevention or treatment of chronic kidney disease in a subject having a high serum uric acid concentration, wherein when administered to a subject having a serum uric acid level of 6 mg / dl or more, the pharmaceutical composition reduces the subject's serum uric acid level to less than 6 mg / dl. Therefore, the pharmaceutical composition according to the present invention exhibits an excellent effect on xanthine oxidase inhibitors, and thus can effectively treat or prevent chronic kidney disease by being administered to a selected subject.